These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 39339909)
21. Ganoderma microsporum immunomodulatory protein acts as a multifunctional broad-spectrum antiviral against SARS-CoV-2 by interfering virus binding to the host cells and spike-mediated cell fusion. Ho HPT; Vo DNK; Lin TY; Hung JN; Chiu YH; Tsai MH Biomed Pharmacother; 2022 Nov; 155():113766. PubMed ID: 36271550 [TBL] [Abstract][Full Text] [Related]
22. SARS-CoV-2 and SARS-CoV Spike-Mediated Cell-Cell Fusion Differ in Their Requirements for Receptor Expression and Proteolytic Activation. Hörnich BF; Großkopf AK; Schlagowski S; Tenbusch M; Kleine-Weber H; Neipel F; Stahl-Hennig C; Hahn AS J Virol; 2021 Apr; 95(9):. PubMed ID: 33608407 [TBL] [Abstract][Full Text] [Related]
23. A SARS-CoV-2 Spike Binding DNA Aptamer that Inhibits Pseudovirus Infection by an RBD-Independent Mechanism*. Schmitz A; Weber A; Bayin M; Breuers S; Fieberg V; Famulok M; Mayer G Angew Chem Int Ed Engl; 2021 Apr; 60(18):10279-10285. PubMed ID: 33683787 [TBL] [Abstract][Full Text] [Related]
24. The Integral Membrane Protein ZMPSTE24 Protects Cells from SARS-CoV-2 Spike-Mediated Pseudovirus Infection and Syncytia Formation. Shilagardi K; Spear ED; Abraham R; Griffin DE; Michaelis S mBio; 2022 Oct; 13(5):e0254322. PubMed ID: 36197088 [TBL] [Abstract][Full Text] [Related]
25. A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry. Xu M; Pradhan M; Gorshkov K; Petersen JD; Shen M; Guo H; Zhu W; Klumpp-Thomas C; Michael S; Itkin M; Itkin Z; Straus MR; Zimmerberg J; Zheng W; Whittaker GR; Chen CZ SLAS Discov; 2022 Mar; 27(2):86-94. PubMed ID: 35086793 [TBL] [Abstract][Full Text] [Related]
26. An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2. Tada T; Fan C; Chen JS; Kaur R; Stapleford KA; Gristick H; Dcosta BM; Wilen CB; Nimigean CM; Landau NR Cell Rep; 2020 Dec; 33(12):108528. PubMed ID: 33326798 [TBL] [Abstract][Full Text] [Related]
27. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics. Barton MI; MacGowan SA; Kutuzov MA; Dushek O; Barton GJ; van der Merwe PA Elife; 2021 Aug; 10():. PubMed ID: 34435953 [TBL] [Abstract][Full Text] [Related]
28. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19). Nayak SK Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074 [TBL] [Abstract][Full Text] [Related]
29. Repositioning of histamine H Ge S; Wang X; Hou Y; Lv Y; Wang C; He H Eur J Pharmacol; 2021 Apr; 896():173897. PubMed ID: 33497607 [TBL] [Abstract][Full Text] [Related]
30. Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein. Van Ert HA; Bohan DW; Rogers K; Fili M; Rojas Chávez RA; Qing E; Han C; Dempewolf S; Hu G; Schwery N; Sevcik K; Ruggio N; Boyt D; Pentella MA; Gallagher T; Jackson JB; Merrill AE; Knudson CM; Brown GD; Maury W; Haim H Microbiol Spectr; 2022 Feb; 10(1):e0267621. PubMed ID: 35080430 [TBL] [Abstract][Full Text] [Related]
31. Structural basis of HCoV-19 fusion core and an effective inhibition peptide against virus entry. Sun H; Li Y; Liu P; Qiao C; Wang X; Wu L; Liu K; Hu Y; Su C; Tan S; Zou S; Wu G; Yan J; Gao GF; Qi J; Wang Q Emerg Microbes Infect; 2020 Dec; 9(1):1238-1241. PubMed ID: 32482145 [No Abstract] [Full Text] [Related]
32. Tinocordiside from Balkrishna A; Pokhrel S; Varshney A Comb Chem High Throughput Screen; 2021; 24(10):1795-1802. PubMed ID: 33172372 [TBL] [Abstract][Full Text] [Related]
33. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity. Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996 [TBL] [Abstract][Full Text] [Related]
34. Chitosan derivatives: A suggestive evaluation for novel inhibitor discovery against wild type and variants of SARS-CoV-2 virus. Modak C; Jha A; Sharma N; Kumar A Int J Biol Macromol; 2021 Sep; 187():492-512. PubMed ID: 34324908 [TBL] [Abstract][Full Text] [Related]
35. Strategies to target SARS-CoV-2 entry and infection using dual mechanisms of inhibition by acidification inhibitors. Prabhakara C; Godbole R; Sil P; Jahnavi S; Gulzar SE; van Zanten TS; Sheth D; Subhash N; Chandra A; Shivaraj A; Panikulam P; U I; Nuthakki VK; Puthiyapurayil TP; Ahmed R; Najar AH; Lingamallu SM; Das S; Mahajan B; Vemula P; Bharate SB; Singh PP; Vishwakarma R; Guha A; Sundaramurthy V; Mayor S PLoS Pathog; 2021 Jul; 17(7):e1009706. PubMed ID: 34252168 [TBL] [Abstract][Full Text] [Related]
36. Inhibition Mechanism of SARS-CoV-2 Infection by a Cholesterol Derivative, Nat-20(S)-yne. Murae M; Sakai S; Miyata N; Shimizu Y; Okemoto-Nakamura Y; Kishimoto T; Ogawa M; Tani H; Tanaka K; Noguchi K; Fukasawa M Biol Pharm Bull; 2024; 47(5):930-940. PubMed ID: 38692871 [TBL] [Abstract][Full Text] [Related]
37. A substrate for a cell free in vitro assay system to screen drugs targeting trypsin like protease-based cleavage of SARS-CoV-2 spike glycoprotein and viral entry. Begum F; Srivastava AK; Tripathi PP; Ray U J Med Virol; 2023 May; 95(5):e28796. PubMed ID: 37218551 [TBL] [Abstract][Full Text] [Related]
39. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites. Qiao B; Olvera de la Cruz M ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067 [TBL] [Abstract][Full Text] [Related]
40. Mechanical activation of spike fosters SARS-CoV-2 viral infection. Hu W; Zhang Y; Fei P; Zhang T; Yao D; Gao Y; Liu J; Chen H; Lu Q; Mudianto T; Zhang X; Xiao C; Ye Y; Sun Q; Zhang J; Xie Q; Wang PH; Wang J; Li Z; Lou J; Chen W Cell Res; 2021 Oct; 31(10):1047-1060. PubMed ID: 34465913 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]